Phase II trial of paclitaxel in patients with advanced colon cancer previously untreated with cytotoxic chemotherapy: An Eastern Cooperative Oncology Group trial (PA286)

Avi I. Einzig; Donna Neuberg; Peter H. Wiernik; Louise B. Grochow; Guillermo Ramirez; Peter J. O'Dwyer; Nicholas J. Petrelli

doi:10.1097/00045391-199611000-00003

Phase II trial of paclitaxel in patients with advanced colon cancer previously untreated with cytotoxic chemotherapy: An Eastern Cooperative Oncology Group trial (PA286)

Avi I. Einzig, Donna Neuberg, Peter H. Wiernik, Louise B. Grochow, Guillermo Ramirez, Peter J. O'Dwyer, Nicholas J. Petrelli

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Paclitaxel was administered as a 24-h continuous infusion at 250 mg/m² in this Phase II trial in patients with adenocarcinoma of the colon or rectum. Nineteen patients were evaluated for toxicity and 15 were assessable for response. There were no complete or partial responses, and toxicity present was primarily neutropenia. This study found that paclitaxel as a single agent does not have activity in adenocarcinoma of the colon or rectum.

Original language	English (US)
Pages (from-to)	750-754
Number of pages	5
Journal	American Journal of Therapeutics
Volume	3
Issue number	11
DOIs	https://doi.org/10.1097/00045391-199611000-00003
State	Published - Nov 1996
Externally published	Yes

Keywords

colon cancer
paclitaxel (Taxol)

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1097/00045391-199611000-00003

Cite this

Einzig, A. I., Neuberg, D., Wiernik, P. H., Grochow, L. B., Ramirez, G., O'Dwyer, P. J., & Petrelli, N. J. (1996). Phase II trial of paclitaxel in patients with advanced colon cancer previously untreated with cytotoxic chemotherapy: An Eastern Cooperative Oncology Group trial (PA286). American Journal of Therapeutics, 3(11), 750-754. https://doi.org/10.1097/00045391-199611000-00003

Phase II trial of paclitaxel in patients with advanced colon cancer previously untreated with cytotoxic chemotherapy: An Eastern Cooperative Oncology Group trial (PA286). / Einzig, Avi I.; Neuberg, Donna; Wiernik, Peter H. et al.
In: American Journal of Therapeutics, Vol. 3, No. 11, 11.1996, p. 750-754.

Research output: Contribution to journal › Article › peer-review

Einzig, AI, Neuberg, D, Wiernik, PH, Grochow, LB, Ramirez, G, O'Dwyer, PJ & Petrelli, NJ 1996, 'Phase II trial of paclitaxel in patients with advanced colon cancer previously untreated with cytotoxic chemotherapy: An Eastern Cooperative Oncology Group trial (PA286)', American Journal of Therapeutics, vol. 3, no. 11, pp. 750-754. https://doi.org/10.1097/00045391-199611000-00003

@article{6e0fb817e0b340c09ac885952567fa2c,

title = "Phase II trial of paclitaxel in patients with advanced colon cancer previously untreated with cytotoxic chemotherapy: An Eastern Cooperative Oncology Group trial (PA286)",

abstract = "Paclitaxel was administered as a 24-h continuous infusion at 250 mg/m2 in this Phase II trial in patients with adenocarcinoma of the colon or rectum. Nineteen patients were evaluated for toxicity and 15 were assessable for response. There were no complete or partial responses, and toxicity present was primarily neutropenia. This study found that paclitaxel as a single agent does not have activity in adenocarcinoma of the colon or rectum.",

keywords = "colon cancer, paclitaxel (Taxol)",

author = "Einzig, {Avi I.} and Donna Neuberg and Wiernik, {Peter H.} and Grochow, {Louise B.} and Guillermo Ramirez and O'Dwyer, {Peter J.} and Petrelli, {Nicholas J.}",

year = "1996",

month = nov,

doi = "10.1097/00045391-199611000-00003",

language = "English (US)",

volume = "3",

pages = "750--754",

journal = "American Journal of Therapeutics",

issn = "1075-2765",

publisher = "Lippincott Williams and Wilkins",

number = "11",

}

TY - JOUR

T1 - Phase II trial of paclitaxel in patients with advanced colon cancer previously untreated with cytotoxic chemotherapy

T2 - An Eastern Cooperative Oncology Group trial (PA286)

AU - Einzig, Avi I.

AU - Neuberg, Donna

AU - Wiernik, Peter H.

AU - Grochow, Louise B.

AU - Ramirez, Guillermo

AU - O'Dwyer, Peter J.

AU - Petrelli, Nicholas J.

PY - 1996/11

Y1 - 1996/11

N2 - Paclitaxel was administered as a 24-h continuous infusion at 250 mg/m2 in this Phase II trial in patients with adenocarcinoma of the colon or rectum. Nineteen patients were evaluated for toxicity and 15 were assessable for response. There were no complete or partial responses, and toxicity present was primarily neutropenia. This study found that paclitaxel as a single agent does not have activity in adenocarcinoma of the colon or rectum.

AB - Paclitaxel was administered as a 24-h continuous infusion at 250 mg/m2 in this Phase II trial in patients with adenocarcinoma of the colon or rectum. Nineteen patients were evaluated for toxicity and 15 were assessable for response. There were no complete or partial responses, and toxicity present was primarily neutropenia. This study found that paclitaxel as a single agent does not have activity in adenocarcinoma of the colon or rectum.

KW - colon cancer

KW - paclitaxel (Taxol)

UR - http://www.scopus.com/inward/record.url?scp=0030432043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030432043&partnerID=8YFLogxK

U2 - 10.1097/00045391-199611000-00003

DO - 10.1097/00045391-199611000-00003

M3 - Article

AN - SCOPUS:0030432043

SN - 1075-2765

VL - 3

SP - 750

EP - 754

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

IS - 11

ER -

Phase II trial of paclitaxel in patients with advanced colon cancer previously untreated with cytotoxic chemotherapy: An Eastern Cooperative Oncology Group trial (PA286)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this